Claims for Patent: 10,744,277

Summary for Patent: 10,744,277

Title:	Aerosol delivery device and method of operating the aerosol delivery device
Abstract:	An aerosol delivery device includes an aerosol generator for generating an aerosol in the aerosol delivery device with a membrane and a vibrator which is configured to vibrate a fluid and to aerosolise the fluid by the membrane. The aerosol delivery device further includes a fluid reservoir for receiving the fluid to be aerosolised, the fluid reservoir being arranged in fluid communication with the membrane, a controller which is configured to sequentially operate the vibrator at a plurality of different vibration frequencies, a sensor which is configured to detect at least one electrical parameter of the vibrator for each of the plurality of different vibration frequencies, and a detector which is configured to detect the presence of fluid in contact with the membrane and/or in the fluid reservoir on the basis of the dependence of the detected values of the at least one electrical parameter on the vibration frequency.
Inventor(s):	Finke; Matthias (Munich, DE), Mutschmann; Dominique (Munich, DE), Achtzehner; Wolfgang (Alling, DE), Holzmann; Philipp (Munich, DE)
Assignee:	PARI Pharma GmbH (Starnberg, DE)
Application Number:	15/104,109
Patent Claims:	1. An aerosol delivery device comprising: an aerosol generator for generating an aerosol in the aerosol delivery device, the aerosol generator comprising a membrane, and a vibrator, which is configured to vibrate a fluid and to aerosolise the fluid by the membrane, a fluid reservoir for receiving the fluid to be aerosolised, the fluid reservoir being arranged in fluid communication with the membrane, a controller which is configured to sequentially operate the vibrator at a plurality of different vibration frequencies, a sensor which is configured to detect at least one electrical parameter of the vibrator for each of the plurality of different vibration frequencies, and a detector which is configured to detect the presence of the fluid in contact with the membrane on the basis of the dependence of the detected values of the at least one electrical parameter on the vibration frequency, wherein the detector is configured to detect the presence of the fluid in contact with the membrane on the basis of a slope or slopes of a curve of the detected values of the at least one electrical parameter as a function of the vibration frequency and on the basis of a length of the curve, wherein the at least one electrical parameter is a voltage and/or a current and/or a power and/or a current/voltage phase shift. 2. The aerosol delivery device according to claim 1, wherein the detector is configured to detect the presence of the fluid in contact with the membrane on the basis of a cross correlation of a curve of the detected values of the at least one electrical parameter as a function of the vibration frequency with a reference curve. 3. The aerosol delivery device according to claim 1, wherein the detector is configured to detect the presence of the fluid in contact with the membrane on the basis of the difference obtained by subtracting a curve of the detected values of the at least one electrical parameter as a function of the vibration frequency obtained in one detection cycle from a curve of the detected values of the at least one electrical parameter as a function of the vibration frequency obtained in another detection cycle. 4. The aerosol delivery device according to claim 1, wherein the detector is configured to detect the presence of the fluid in contact with the membrane on the basis of an area under a curve of the detected values of the at least one electrical parameter as a function of the vibration frequency. 5. The aerosol delivery device according to claim 1, wherein the detector is configured to detect the presence of the fluid in contact with the membrane on the basis of a Fourier transform of a curve of the detected values of the at least one electrical parameter as a function of the vibration frequency. 6. The aerosol delivery device according to claim 1, wherein the controller is configured to deactivate the vibrator if no presence of the fluid in contact with the membrane is detected by the detector. 7. The aerosol delivery device according to claim 1, wherein the controller is configured to sequentially operate the vibrator at 40 or more different vibration frequencies of the plurality of different vibration frequencies. 8. The aerosol delivery device according to claim 1, wherein the controller is configured to switch the vibrator from one vibration frequency to the next vibration frequency of the plurality of different vibration frequencies within a time period of 20 ms or less. 9. The aerosol delivery device according to claim 1, wherein the controller is configured to sequentially operate the vibrator at the plurality of different vibration frequencies in the range of 30 to 60 kHz and/or 90 to 170 kHz and/or 350 to 600 kHz. 10. The aerosol delivery device according to claim 1, wherein the controller is configured to sequentially operate the vibrator at the plurality of different vibration frequencies so that the difference between one vibration frequency and the next vibration frequency is not more than 3% of the one vibration frequency. 11. The aerosol delivery device according to claim 1, wherein the controller is configured to sequentially operate the vibrator at the plurality of different vibration frequencies so that the difference between one vibration frequency and the next vibration frequency is a function of the vibration frequencies. 12. The aerosol delivery device according to claim 1, wherein the membrane is a passive membrane and the vibrator is configured to vibrate a fluid supply system and/or a membrane back space of the aerosol delivery device. 13. The aerosol delivery device according to claim 1, wherein the membrane is an active membrane and the vibrator is configured to vibrate the membrane. 14. A method of operating an aerosol delivery device, the aerosol delivery device comprising: an aerosol generator for generating an aerosol in the aerosol delivery device, the aerosol generator comprising a membrane, and a vibrator which is configured to vibrate a fluid and to aerosolise the fluid by the membrane, and a fluid reservoir for receiving the fluid to be aerosolised, the fluid reservoir being arranged in fluid communication with the membrane, the method comprising the steps of: sequentially operating the vibrator at a plurality of different vibration frequencies, detecting at least one electrical parameter of the vibrator for each of the plurality of different vibration frequencies, and detecting the presence of the fluid in contact with the membrane on the basis of the dependence of the detected values of the at least one electrical parameter on the vibration frequency, wherein the presence of the fluid in contact with the membrane is detected on the basis of a slope or slopes of a curve of the detected values of the at least one electrical parameter as a function of the vibration frequency and on the basis of a length of the curve, wherein the at least one electrical parameter is a voltage and/or a current and/or a power and/or a current/voltage phase shift. 15. The method of operating an aerosol delivery device according to claim 14, wherein the membrane is a passive membrane and the vibrator is configured to vibrate a fluid supply system and/or a membrane back space of the aerosol delivery device. 16. The method of operating an aerosol delivery device according to claim 14, wherein the membrane is an active membrane and the vibrator is configured to vibrate the membrane. 17. The method of operating an aerosol delivery device according to claim 14, wherein the fluid to be aerosolised contains one or more active agents, the one or more active agents being selected from the group consisting of an anti-epileptic drug, an anti-convulsive drug, an anti-emetic, a immunemodulator, a pain killer, an anti-rheumatic, an anti-cancer drug, a mucolytic drug, a sleeping assistant, an anti-mycotic, a sexual stimulant, a protein or peptide, heparane and a gene, and/or the group consisting of an anti-diabetic drug, insulin and a hormone, and/or the group consisting of a corticosteroid, a leukotriene antagonist, a bradykinin antagonist, a cromone, an anti-histamine and an antibody, and/or the group consisting of an aminoglycoside, a cephalosporine, a macrolide, a chonolone, a nitroimidazol, a glycopeptide, a polyen-antibiotic, a beta-lactam, a tetracycline, a quinolone, a sulfonamide, and an azol derivative, and/or the group consisting of a benzodiazepine, a barbitute and a succinimide, and/or the group consisting of alpha antitrypsine, erythropoetine, interferones, kinases, elastases, peptides and proteines, and/or the group consisting of salbutamol, levalbuterol, formoterol, fenoterol, salmeterol, bambuterol, brocaterol, clenbuterol, terbutalin, tulobuterol, epinephrin, isoprenalin, and hexoprenalin, and/or the group consisting of tiotropium, oxitropium, ipratropium, and glcopyrrolate, and/or the group consisting of acetylcystein, ambroxol, carbocystein, tyloxapol, dipalmytoylphosphatidylcholin, recombinant surfactant proteins, and D-Nase, and/or the group consisting of surfactants, and/or the group consisting of cromoglycate, nedocromil, beclomethasone, betamethasone, budesonide, ciclesonide, flunisolide, fluticasone, icomethasone, mometasone, rofleponide, triamcinolone, bradykinine-, prostaglandine-, leucotriene- and platelet activating factor antagonists, and/or the group consisting of amoxycillan, piperacillin, clavulan acid, sulbactam, cefaclor, cefazedon, Cefuroxim, Cefoxitin, cefodizim, cefsulodin, cefpodixim, cefixim, colistin, imipenem, cilastatin, az-trenonam, streptomycin, neomycin, paromomycin, kanamycin, gentamycin, amicacin, tobramycin, spectinomycine, doxycyclin, minocycline, erythromycine, clarithromycine, roxithromycine, azithromycine, josamycine, spiramycine, Ciprofloxacin, Ofloxacine, Levofloxacine, pefloxacine, lomefloxacine, fleroxacine, clinafloxacine, sitafloxacine, gemifloxacine, balofloxacine, trovafloxacine, moxifloxacine, metronidazol, tinidazol, chloramphenicol, lincomycine, clindamycine, fosfomycine, vancomycine and teicoplanine, and/or the group consisting of refampicine, isoniacide, cycloserine, terizidone, and ansamycine, and/or the group consisting of clotrimazol, oxiconazol, miconazol, ketoconazol, itraconazol, fluconazol, amphotericine B, natamycine, nystatine, flucytosine, and Pentamidine, and/or the group consisting of dimepranol-4-acetate amideo benzoate, thymopentin, interfer-ones, filgrastine, interleukine, azathioprine, and cyclosporine; virustatics such as podophyllotoxine, vidarabine, tromantadine, zidovudine, and a-antitrypsin, and/or the group consisting of corticotro-pine, tetracosactide, choriogonandotropine, urofolitropine, urogonadotropine, saomatotropine, metergoline, desmopres sine, oxytocine, argipressine, or-nipressine, leuproreline, triptoreline, gonadoreline, busereline, nafareline, goselerine, somatostatine, parathyroide gland hormones, Dihydrotachysterole, calcitonine, clodron acid, etidron acid, thyroid gland therapeutics, anabolics, androgens, etrogens, gestagenes, and antiestrogenes, and/or the group consisting of nimustine, melphanlane, carmustine, lomustine, cyclophosphosphamide, ifosfamide, trofosfamide, chlorambucil, busulfane, treosulfane, prednismustine, thiotepa, cytarabine, fluorouracil, mercaptopurine, tioguanine, vinblastine, vincristine, vindesine, alcarubicine, bleomycine, dactinomycine, daunorubicine, doxorubicine, epirubicine, idarubicine, mitomycine, plicamycine, carboplatinum, cis-platinum, titanocendichloride Amsacrine, dacarbazine, estramustine, etoposide, hydroxycarbamide, mitoxanthrone, procarbazine, and temiposide, and/or the group consisting of Proxibarbal, lisuride, methysergide, dihydroergotamine, ergotamine, clonidine, pizotifene, bezodiazepines, barbiturates, cyclopyrrolones, imidazopyridines, arbiturates, Pheytoin, Primidone, mesuximide, ethosuximide, sultiam, carbamezepin, valproic acid, vigabatrine, Levodopa, carbidopa, benserazide, selegiline, bromocriptine, amantadine, tiapride, Thiethylperazine, bromopride, domperidone, granisetrone, ondasetrone, tropisetrone, pyridoxine, morphine, codeine, hydromorphone, methadone, fenpipramide, fentanyl, piritramide, pentazocine, buprenorphine, nalbuphine, tilidine, N-methylated barbiturates, thiobarbiturates, ketamine, etomidate, propofol, benzodiazepines, droperidol, haloperidol, alfentanyl, sulfentanyl, tumor necrosis factor alpha and non-steroidal anti-inflammatory drugs, and/or the group consisting of insulin, sulfonylurea derivatives, biguanids, glitizols, glucagon, diazoxid, interleukines, interferones, tumor necrosisfactor (TN F), and colony stimulating factors, and/or the group consisting of proteins, peptides, heparine, heparinoids, urokinases, streptokinases, ATP-ase, prostacycline, sexual stimulants, and genes. 18. The method of operating an aerosol delivery device according to claim 14, wherein the fluid to be aerosolised contains one or more active agents including monobactams. 19. The method of operating an aerosol delivery device according to claim 14, wherein the fluid to be aerosolised contains one or more active agents including aztreonam.